The FDA accepts Vertex's (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
The latest bull market has plenty of intriguing buying opportunities.
Growth stocks with wide moats and strong financials can compound investor returns with time.